Skip to content
value.today

Cellectis S.A.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to salesPrice to sales of Biotechnology: $163 M to $736 M, median $361 MPrice to bookPrice to book of Biotechnology: $235 M to $936 M, median $345 M$0 M$253 M$505 M$758 M$1.0 B

Your own DCF model

A full discounted-cash-flow model of Cellectis S.A., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Biotechnology

Multiples of its companies with a market value at most 60 days old, times Cellectis S.A.'s own figures of FY2025.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)Cellectis S.A.Applied toValue (25th to 75th)Companies
Price to sales2.2× / 5.0× / 10.1×—revenue $73 M$163 M to $736 M85
Price to book3.1× / 4.5× / 12.3×—book equity $76 M$235 M to $936 M70

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Cellectis S.A.'s multiples at each month end with a market cap on file, Jan 2020 to Jan 2024, each against its own median.

Price to sales

11.3×

Now above its median of 9.2×; range 3.1× to 83.2× over 6 months.

0×21×42×62×83×20202021202220232024Price to sales 11×Median 9×

Price to book

1.8×

Now above its median of 1.6×; range 0.4× to 4.0× over 6 months.

0×1×2×3×4×20202021202220232024Price to book 2×Median 2×

as of Jan 5, 2024. Market caps: the dated values on file since 2020. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Jan 5, 2024.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2025to Dec 31, 2025$73 M$-68 M$-39 M$2 M$-42 M—SEC annual report (10-K, 20-F)
FY2024to Dec 31, 2024$42 M$-37 M$23 M$3 M$20 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$1 M$-101 M$-25 M$1 M$-26 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$19 M$-106 M$-87 M$2 M$-90 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$30 M$-114 M$-105 M$19 M$-123 M—SEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$51 M$-81 M$-80 M$44 M$-124 M—SEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value not on file.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.